Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZAK-CKD: Zinc acetate hydrate in chronic kidney disease with hypozincemia
jRCTs061210030Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of zinc acetate in chronic kidney disease (CKD) (2 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoint: Primary composite renal endpoint. Started Jan 2022; status: completed.
02
Drugs
zinc acetate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs061210030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210030.